TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7521636
Drug: WCPDT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCPDT vaccine
Study: 2658335
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml NaCl with 25 ml Ginkgo‐biloba‐extract
Study: 19714349
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid (n = 12)
Study: 15793525
Drug: Tri-herbal combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-herbal combination of Eleutherococcus, Achillea millefolium, and Lamium album
Study: 12483453
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg day(-1))
Study: 18694678
Drug: Two-compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound scalp formulation (calcipotriene 50 microg/g plus betamethasone 0.5 mg/g)
Study: 26443484
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine oral rinse
Study: 24528246
Drug: High-dose metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metformin (50% reduction)
Study: 21067837
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of glimepiride
Study: 22958507
Drug: WATER therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATER therapy program (24 sessions, 3 times/week over 8 weeks) of low-intensity exercises in a warm pool (32°C)
Study: 22958507
Drug: WATER therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATER therapy program
Study: 15964291
Drug: Nestorone/ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone/ethinyl estradiol rings (all doses)
Study: 8325044
Drug: Diclofenac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (150 mg/day)
Study: 10064240
Drug: Itraconazole, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 2.5 mg/kg every 12 hours
Study: 15112862
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Penopril)
Study: 11453894
Drug: Modified prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified prescriptions
Study: 11453894
Drug: Non-printed prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-printed prescriptions (multivariate analysis)
Study: 11453894
Drug: Overall correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall correction of prescriptions in Dutch community pharmacies
Study: 7996373
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg nebulized furosemide per kg
Study: 7996373
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg nebulized furosemide per kg
Study: 7996373
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg nebulized furosemide per kg
Study: 7996373
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nebulized furosemide per kg
Study: 9117181
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy at Vichy (France) for 3 weeks
Study: 15378139
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy (control group)
Study: 3704978
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline started 30 minutes before exercise and continued throughout the 60 minute recovery period
Study: 3704978
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline started immediately after the end of exercise
Study: 31324081
Drug: Glimepiride-Metformin
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride-Metformin
Study: 1350696
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg in three doses)
Study: 1350696
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg in three doses)
Study: 28933611
Drug: Medium-frequency (MG:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-frequency (MG: 40Hz x 360s)
Study: 27488192
Drug: l-mequitazine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-mequitazine 5.0 mg
Study: 27488192
Drug: l-mequitazine 10
Normalized name: mequitazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-mequitazine 10 mg
Study: 27488192
Drug: mequitazine 10
Normalized name: mequitazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mequitazine 10 mg
Study: 16949482
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel loading dose
Study: 16949482
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel loading dose
Study: 16897237
Drug: Landiolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.2 mg x kg(‐1)
Study: 16897237
Drug: Landiolol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 0.1 mg x kg(‐1)
Study: 8560679
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily) plus LHRH analogue (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Study: 8560679
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Study: 8560679
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg once daily)
Study: 8708714
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg three times daily)
Study: 1991673
Drug: Felodipine (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (twice daily for 2 months)
Study: 2038732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and terbutaline
Study: 31248471
Drug: GSP301 (olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSP301 (olopatadine 665 μg and mometasone 25 μg)
Study: 22737864
Drug: Stronger neo-minophagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stronger neo-minophagen C 100 mL dissolved in 10% dextrose 250 ml once a day intravenously, combined with decoction of turtle shell for anti-fibrosis one powder daily
Study: 19940840
Drug: HB‐AS02 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS02 (three doses at 0, 1, and 6 months)
Study: 19940840
Drug: HB‐AS04 (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS04 (four doses at 0, 1, 2, and 6 months)
Study: 12406033
Drug: Glyburide/metformin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin 2.5 mg/500 mg
Study: 12406033
Drug: Glyburide/metformin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin 5 mg/500 mg
Study: 12406033
Drug: Glyburide 10
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 10 mg b.i.d.
Study: 12635468
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg daily for 6 weeks, increased to 20 mg daily if LDL cholesterol goal not achieved
Study: 12635468
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily for 6 weeks, increased to 20 mg daily if LDL cholesterol goal not achieved
Study: 10337458
Drug: Topical dimethindene
Normalized name: dimethindene
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dimethindene maleate (DMM) gel
Study: 19786668
Drug: GC (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC (gemcitabine 1,000 mg/m(2) on days 1 and 8 and carboplatin AUC 4.5 for 21 days)
Study: 19786668
Drug: M-CAVI (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-CAVI (methotrexate 30 mg/m(2) on days 1, 15, and 22; carboplatin AUC 4.5 on day 1; and vinblastine 3 mg/m(2) on days 1, 15, and 22 for 28 days)
Study: 16202854
Drug: Felodipine +
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine + Metoprolol (F+M) 5 + 50 mg
Study: 27881011
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy only
Study: 10021304
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy only (specifically for stage III patients)
Study: 17432689
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy plus Chinese medicinal compound for EWEPPB
Study: 17432689
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western therapy alone
Study: 15803833
Drug: Cytostatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic and antibacterial agents
Study: 10632027
Drug: Histamine injection
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine injection in area of allodynia (experimental arm)
Study: 10632027
Drug: Histamine injection
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine injection in opposite forearm (control arm)
Study: 7717489
Drug: Routine thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine thermal management (circulating-water mattress set at 42 degrees C, intravenous fluid warming to 37 degrees C and passive insulation)
Study: 31252032
Drug: Dupilumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (200 mg weekly)
Study: 22101225
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy delivered in-person
Study: 10821361
Drug: Losartan (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (titrated to 50 mg once daily)
Study: 10821361
Drug: Captopril (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (titrated to 50 mg three times daily)
Study: 8773906
Drug: Alanine aminotransferase
Normalized name: Alanine aminotransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanine aminotransferase > or = 300 U/l at entry
Study: 30808080
Drug: udenafil 50
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil 50 mg (U50)
Study: 30808080
Drug: udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil 100 mg (U100)
Study: 22926591
Drug: Fluvoxamine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (titrated up to 150 mg/d)
Study: 17660033
Drug: Long-term rapamycin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term rapamycin treatment
Study: 16098002
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg/day (acute treatment)
Study: 12137725
Drug: Pentoxifylline 1200
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 1200 mg per day (3 x 400 mg) orally in addition to local therapy
Study: 28421294
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy combined with intravesical chemotherapy (group A)
Study: 28421294
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy alone (group B)
Study: 28840277
Drug: 70 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 kVp with 25 mL contrast medium (CM)
Study: 28840277
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp with 40 mL contrast medium (CM)
Study: 24012432
Drug: TAP (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP (loading dose aspirin 300 mg, clopidogrel 600 mg, cilostazol 200 mg)
Study: 12431323
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin-based regimens)
Study: 2537566
Drug: Lisinopril (readministration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (readministration after 12 weeks)
Study: 19493352
Drug: PCT-guided antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided antibiotic therapy (discontinued if PCT <1 ng/ml or dropped to 25-35% of initial value over three days)
Study: 19493352
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic regimen (applied over eight days)
Study: 15571523
Drug: Melatonin (6-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6-9 mg/day for 14 days)
Study: 27690710
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla‐300) with patient support program
Study: 11759128
Drug: Esmolol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 0.4 mg/kg
Study: 195920
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment
Study: 6356897
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 to 400 mg three times a day)
Study: 9580448
Drug: Metamizol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol 1 g
Study: 12359036
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management + patch
Study: 12359036
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention + patch
Study: 10092007
Drug: Ad5 wt
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ad5 wt vaccine
Study: 26915026
Drug: 8.4% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.4% sodium bicarbonate infusion (0.5 mEq/kg/h for the first hour; 0.15 mEq/kg/h until completion of surgery)
Study: 23061240
Drug: Hydrocodone daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone daily for 30 days (in smokers)
Study: 23061240
Drug: Hydrocodone daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone daily for 30 days (in nonsmokers)
Study: 17275657
Drug: Intravenous valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate infusion at doses ranging from 7.5 to 41.5 mg/kg and rates of 1.5 to 11 mg/kg per minute
Study: 29229058
Drug: Qigong therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong therapy
Study: 11795622
Drug: Medication (lofexidine‐HCl)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (lofexidine‐HCl)
Study: 1688066
Drug: Terbutaline nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline nebulizer inhalation
Study: 1688066
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment (both groups)
Study: 7370603
Drug: Behringwerke antivenom
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behringwerke antivenom (60-180 ml)
Study: 24908656
Drug: Veliparib 25
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 25 mg/m² b.i.d. and TMZ 135 mg/m²/d
Study: 21926667
Drug: MEDI-534 (live,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-534 (live, attenuated RSV/PIV3 chimeric virus vaccine candidate)
Study: 17157557
Drug: Simple oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oral explanation (SP) + Single home visit (SH)
Study: 17157557
Drug: Simple oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple oral explanation (SP) + Repeated home visits (RH)
Study: 17157557
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and written explanation (RP) + Single home visit (SH)
Study: 21244738
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (PSS)
Study: 9609266
Drug: Oral oestriol
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestriol (3 mg per day)
Study: 30881102
Drug: Oliceridine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine 0.1 mg
Study: 30881102
Drug: Oliceridine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine 0.5 mg
Study: 31162798
Drug: Gastrointestinal adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrointestinal adverse events with Oliceridine 0.1 mg
Study: 31162798
Drug: Gastrointestinal adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrointestinal adverse events with Oliceridine 0.35 mg
Study: 31162798
Drug: Gastrointestinal adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrointestinal adverse events with Oliceridine 0.5 mg
Study: 31162798
Drug: Oliceridine 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine 0.35 mg and 0.5 mg
Study: 16538534
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 or 600 mg daily for 2 weeks)
Study: 8855737
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and clarithromycin 250 mg (OC)
Study: 8855737
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 500 mg (OCM)
Study: 1281043
Drug: Internal radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal radiation therapy by transcatheter hepatic arterial injection of [131I]‐Lp (group A)
Study: 1281043
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Lp‐TAE (group B)
Study: 22920718
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 50‐300 mg/day
Study: 22920718
Drug: Divalproex ER
Normalized name: divalproex sodium Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex ER 500‐3000 mg/day
Study: 25511384
Drug: Ascophyllum nodosum
Normalized name: Ascophyllum nodosum
DrugBank: Ascophyllum nodosum (DB16591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascophyllum nodosum (500 mg dried marine alga powder, ProDen PlaqueOff®)
Study: 25511384
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control tablets
Study: 3709647
Drug: Cisapride (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (8 mg)
Study: 20514787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CO2 fractional resurfacing and Kligman's formula maintenance topical cream (Group C)
Study: 7734231
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment including hip and knee release, aponeurectomy of the iliotibial band, and z-shaped Achilles' tendon lengthening in group I (prophylactic treatment)
Study: 7734231
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment including hip and knee release, aponeurectomy of the iliotibial band, and z-shaped Achilles' tendon lengthening in group II (treatment for existing contractures)
Study: 22822019
Drug: Active spinal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active spinal anesthesia with fentanyl (25 μg, intrathecal L(3)‐L(4))
Study: 16142016
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg x 2/day)
Study: 394563
Drug: Oral bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromocriptine (5 mg dd for 14 days)
Study: 394563
Drug: Oral stilbestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stilbestrol (15 mg dd for 5 days)
Study: 394563
Drug: Diuretic compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic compound (bendroflumethazide 15 mg dd for 5 days)
Study: 23421781
Drug: Amoxycillin-clavulanate (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanate (22.5 mg/kg twice daily)
Study: 23421781
Drug: Azithromycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5 mg/kg daily)
Study: 21878810
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with ketamine
Study: 21878810
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with morphine
Study: 11905957
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil diet (80 g corn oil/d)
Study: 3067654
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg bromocriptine at bedtime
Study: 16909787
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for TBE meningitis
Study: 1482871
Drug: Computer-assisted interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted interventions (various types including reminder, feedback, dose planning, patient education, medical record)
Study: 31248950
Drug: Esaxerenone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esaxerenone 2.5 mg/d
Study: 24502414
Drug: customary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: customary treatment plus active physiotherapy
Study: 21058474
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and medication (Thiamazole and Euthyrox)
Study: 12422105
Drug: Thigh-length sequential
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thigh-length sequential EPC devices (EPC)
Study: 12422105
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin injections (HEP)
Study: 2038996
Drug: Naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1000 mg daily for 7 days)